Considering anticancer role, fisetin has been found to exhibit effectual role against different human oral squamous cell including Tca‐8113 and UM‐SCC‐23 cancer cell lines through multiple pathways, that is, suppression of Met/Src signaling pathways, inhibition of level of a disintegrin and metalloproteinase 9 (ADAM9) protein, and reduction in basal expression of Met and Src protein, respectively (Li, Qin, & Dai, 2017). Here, SRC is linked to cancer.